With decades of experience, WuXi Advanced Therapies’ provides a time-sensitive solution for production of high-quality Lentiviral vectors that meet your development timeline needs. 

Our integrated single-source, in-house platform offers in-stock raw materials with established batch records, enhanced manufacturing scalability and flexibility, and complete testing capabilities.

Platform Features

• Industry-leading experience with robust scalability and consistent predictability.
• A honed two-tier development paradigm (EDP/LDP) with a closed system of end-to-end integrated solutions that speeds entry to the clinic.
• Dedicated process and analytical development teams to support feasibility studies and verification runs.
• A state-of-the-art GMP manufacturing facility – for both adherent and suspension production – that offers enhanced capacity and scheduling flexibility to meet customer timelines.
• Characterized MCB and WCB ready for client production and a secure supply with raw materials and consumables in stock – ready for use – with established batch records.
• Full in-process and release testing, plus complete quality control and characterization services with regulatory support.
• Consistent product quality and productivity when process is scaled up, and downstream process that typically results in 20-40% overall yield in viral particle.